

# PRESS RELEASE

## Cevidra SAS and AFYX Therapeutics A/S announces distribution and collaboration agreement

### **Cevidra SAS and AFYX Therapeutics A/S announces distribution and collaboration for France.**

Hørsholm, Denmark January 13th, 2025  
AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing innovative treatments for Head and Neck Cancer to the French market.

Under this collaboration, Cevidra will serve as the local pharmaceutical Exploitant and distribution partner in France, leveraging its expertise to support AFYX in the introduction of new therapies to healthcare professionals.

About Cevidra and AFYX pharmaceutical companies seeking to commercialize medicines through Early Access Programs (AAC, AAP) or Licensed Products (MA).

**Claus Møller-San Pedro**  
CEO & Founder

As a one-stop company, Cevidra offers fully integrated solutions, including price and reimbursement, local pharmacovigilance, CRO services for data collection, distribution, and tailored promotional activities. Cevidra, with its Exploitant status, is the gateway to the French market for

AFYX - Reversed Innovation is our core value. As a leader in the biopharmaceutical industry, reversed innovation aligns with the broader theme, as we take an existing product or technology and use it to address a new or previously overlooked or unconsidered medical problem or condition.

For more information: <https://afyxtx.com>

For more information please contact:  
Helle Heidensleben;  
[hh@afyxtx.com](mailto:hh@afyxtx.com); +453162 7798  
Loïc Fiévet ;  
[l.fievet@cevidra.com](mailto:l.fievet@cevidra.com); +33493705831

